Shared on01 Aug 25Fair value Decreased 46%
Despite an increase in forecasted revenue growth, Pulmonx's significant decline in Future P/E suggests reduced investor confidence in earnings quality or sustainability, prompting a notable drop in the consensus analyst price target from $12.50 to $9.25. What's in the News Pulmonx Corporation lowered full-year 2025 revenue guidance to $90–92 million, down from prior expectations of $96–98 million.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 10%
AnalystConsensusTarget has increased future PE multiple from 31.0x to 36.2x and decreased shares outstanding growth rate from 0.0% to 0.0%.